S&P 500 7,811.54 +0.59%Nasdaq 27,366.17 +0.64%Dow 51,654.95 +0.83%Russell 2000 2,806.98 +0.46%as of 2026-10-09 close
▚ The MicroCap Herald
Micro-cap and nano-cap intelligence, before the crowd
Market Pulse

Edible Garden Regains Nasdaq $1.00 Bid-Price Compliance; the Hearings Panel Keeps Jurisdiction Through Nov. 23

The controlled-environment agriculture company said on Sept. 2 that Nasdaq had confirmed it has regained compliance with the $1.00 minimum closing bid price rule. The company said in July that its closing bid price had stayed at or above $1.00 since a 1-for-45 reverse split took effect on July 13, and the Panel that granted continued listing retains jurisdiction through Nov. 23.
Illustrative photograph: stock-market trading screens showing price charts.

Edible Garden AG Incorporated (Nasdaq: EDBL, EDBLW) said in a release issued at 07:28 ET on Sept. 2, 2026 that it had received a letter from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), the requirement to maintain a minimum closing bid price of $1.00 per share. The confirmation follows the decision of a Nasdaq Hearings Panel that the company announced on July 28, 2026.

The company effected a 1-for-45 reverse stock split with an effective date of July 13, 2026. In its July 28 announcement it said that since the reverse stock split became effective, the closing bid price of its common stock had remained at or above $1.00 per share. A reverse split raises the quoted price arithmetically by reducing the share count; it does not by itself alter revenue, cash, losses or the underlying demand for the shares. Neither release the Herald reviewed attributes the regained compliance to any change in the operating business.

The Panel has not finished with the company

The July 28 announcement set out the terms on which continued listing was granted. The Panel granted the company's request for continued listing contingent on demonstrating compliance with Rule 5550(a)(2) by Aug. 15, 2026, and stated that it would maintain jurisdiction over the company's listing through Nov. 23, 2026. That monitoring period is still running. Regaining bid-price compliance closes one condition; it does not end the Panel's jurisdiction, which on the company's own account extends through Nov. 23.

Two details in the Sept. 2 release are worth noting for what they omit. The release does not state the number of consecutive business days over which the closing bid price was at or above $1.00, nor the specific date range Nasdaq relied on. It also does not explain the interval between the Panel's stated Aug. 15 compliance deadline and the Sept. 2 date of the confirmation letter. The Herald reports both dates as the company stated them and draws no inference from the gap.

The financial picture behind the listing

The figures below are taken from the company's second-quarter results release of Aug. 14, 2026, covering the three and six months ended June 30, 2026. They are roughly two months old, they predate the Sept. 2 compliance confirmation, and they do not reflect any financing, spending or share issuance since the balance sheet date. The release presented no adjusted EBITDA or other non-GAAP measure; the figures are as the release presented them.

For the second quarter the company reported revenue of $3.6m against $3.1m a year earlier, which the release headlined as a 12.8% increase, with gross profit of $0.6m in both periods and a net loss of $3.3m against $4.0m. For the six months it reported revenue of $6.9m against $5.9m and a net loss of $6.9m against $7.4m. The Herald reports these at the level of precision the release presented and has not reconciled them to the financial statements in the corresponding SEC filing.

The same release reported cash and cash equivalents of $658,000 as of June 30, 2026, and 525,638 shares of common stock outstanding as of that date, a figure the company footnoted as adjusted to reflect the stock splits. Both are stated here as reported. The Herald draws no conclusion about liquidity, runway or solvency from the cash figure, and readers should not read one into its inclusion.

The Herald did not retrieve and review the corresponding quarterly report on Form 10-Q for this article, and therefore makes no statement about whether that filing contains going-concern language or a specific liquidity disclosure. The Aug. 14 results release the Herald did review contained no going-concern or substantial-doubt language. Readers who want that assessment should consult the filing itself rather than infer it from the figures above.

In the Sept. 2 release, chief executive Jim Kras described regaining compliance as an important development for the company and said it allows Edible Garden to keep its focus on executing its growth strategy. In the July 28 announcement he indicated the company's attention was on its Webster City facility and on cost reduction initiatives. Both characterisations are the company's own and are reported here in indirect speech.

Micro-cap and nano-cap securities carry substantial risk, including the possible total loss of an investment. Liquidity is frequently thin and a quoted price may not be obtainable in any meaningful size, a point that applies with particular force to a company with a share count in the hundreds of thousands following a 1-for-45 consolidation. Compliance with one continued listing standard does not establish compliance with the others, and a company under Hearings Panel jurisdiction remains subject to that Panel's conditions.

The Herald does not offer investment advice, does not publish price targets, and takes no view on whether this security should be bought or sold. The dates on the record are Nov. 23, 2026, when the Panel's stated jurisdiction runs to, and July 13, 2026, when the reverse split that produced the compliant bid price took effect.

This article is for general information only and is not investment advice. Figures are as reported by the cited sources at time of writing.

Related coverage

Illustrative photograph: US banknotes and coins.
Market Pulse

Eleven Small-Company Reverse Splits Took Effect Between Sept. 28 and Oct. 8, From 1-for-10 to 5,000-for-1. Under Nasdaq Rule 5810(c)(3)(A)(iv), Each of the Seven Nasdaq Names on the List Has No Cure Period if Its Bid Fails the $1 Test Within a Year.

8-Ks on EDGAR show seven Nasdaq, two NYSE American and two OTC consolidations among the micro- and small-caps we tracked, with two more Nasdaq splits set for Oct. 12; the list is not exhaustive. Vivakor's 1-for-15 follows a 1-for-20 in July, a cumulative 300-to-1 by our arithmetic, above the rule's 250-to-1 two-year threshold.

Wesley Stroud · October 10, 2026
Illustrative photograph: a printed financial chart and market data.
Market Pulse

The Russell 2000 Was the Only Major Index to Fall in the Week to Oct. 9, Down 0.91%, While the Micro-Cap ETF Lost 1.97% and Three IPOs Priced, One of Them a SPAC

TheStreet's 4 p.m. wrap put the Russell 2000 at 2,808.57 on Friday; Nasdaq's historical table shows the iShares Micro-Cap ETF closing at 183.00, from 186.68 a week earlier. Renaissance Capital counted two biotech IPOs and one blank-check pricing, plus ten new filings, in the week of Oct. 5.

Wesley Stroud · October 10, 2026
Illustrative photograph: stock-market trading screens showing price charts.
Market Pulse

bioAffinity clears two Nasdaq deficiencies and its hearing is cancelled, leaving about 592,373 shares outstanding

A Nasdaq letter dated Sept. 8 confirmed compliance with both the minimum bid price rule and the rights-and-warrants rule, cancelling a Hearings Panel appearance the company had been pushed into because a reverse split within the prior year disqualified it from any cure period. Two splits in eleven months compound to 450-to-1, above the 250-to-1, two-year threshold written into the same rule.

Wesley Stroud · September 10, 2026